Current Treatment Options for Metastatic, Castrate-Resistant Prostate Cancer
View next
Published on October 28, 2014
Dr. Neal Shore, a noted prostate cancer researcher, explores what is available today for men with metastatic, castrate-resistant prostate cancer(mCRPC). Dr. Shore explains why he feels, after new medicines no longer work, patients should not fear chemotherapy.
This content was provided by the Patient Empowerment Network, which received an unrestricted educational grant from Bayer Oncology.